BACKGROUND: The sensitivity of albuminuria in predicting loss of kidney function has been questioned. We determined the sequence of kidney disease stages (microalbuminuria, macroalbuminuria, low estimated glomerular filtration rate [eGFR], and end-stage renal disease [ESRD]) and characterized those without albuminuria before a low eGFR. STUDY DESIGN: The Pittsburgh Epidemiology of Diabetes Complications Study is a prospective cohort investigation of childhood-onset type 1 diabetes. SETTING & PARTICIPANTS: 480 study participants with eGFR greater than 60 mL/min/1.73 m(2) (mean age, 27 years; diabetes duration, 19 years at study entry) were prospectively followed up for 16 years. OUTCOMES & MEASUREMENTS: Low eGFR was defined as creatinine clearance less than 60 mL/min/1.73 m(2) from timed urine collections; microalbuminuria, as albumin excretion rate between 20 to 200 microg/min (30 to 300 mg/24 h); macroalbuminuria, as albumin excretion rate greater than 200 microg/min (>300 mg/24 h); and ESRD, as dialysis or renal transplantation. RESULTS: The 33 of 480 individuals (7%) who developed ESRD had prior albuminuria. 71 of 480 (15%) individuals developed low eGFR. 66 of 71 (93%) had prior/concurrent albuminuria, and 5 of 71 (7%) did not. Incident low eGFR values in the 5 patients were: (1) 54, (2) 58, (3) 59, (4) 59.7, and (5) 59.8 mL/min/1.73 m(2). 3 of 5 (60%; patients 1, 4, and 5) subsequently developed albuminuria. Final eGFRs in the 5 patients were: (1) 94, (2) 86, (3) 60, (4) 65, and (5) 54 mL/min/1.73 m(2), respectively. LIMITATIONS: GFR and insulin sensitivity were not measured, but estimated. Incident decreased eGFR in patients without preceding/concurrent albuminuria may be caused by misclassification or a temporary eGFR decrease. CONCLUSIONS: Moderately decreased eGFR may occur rarely in patients with type 1 diabetes without preceding albuminuria.
BACKGROUND: The sensitivity of albuminuria in predicting loss of kidney function has been questioned. We determined the sequence of kidney disease stages (microalbuminuria, macroalbuminuria, low estimated glomerular filtration rate [eGFR], and end-stage renal disease [ESRD]) and characterized those without albuminuria before a low eGFR. STUDY DESIGN: The Pittsburgh Epidemiology of Diabetes Complications Study is a prospective cohort investigation of childhood-onset type 1 diabetes. SETTING & PARTICIPANTS: 480 study participants with eGFR greater than 60 mL/min/1.73 m(2) (mean age, 27 years; diabetes duration, 19 years at study entry) were prospectively followed up for 16 years. OUTCOMES & MEASUREMENTS: Low eGFR was defined as creatinine clearance less than 60 mL/min/1.73 m(2) from timed urine collections; microalbuminuria, as albumin excretion rate between 20 to 200 microg/min (30 to 300 mg/24 h); macroalbuminuria, as albumin excretion rate greater than 200 microg/min (>300 mg/24 h); and ESRD, as dialysis or renal transplantation. RESULTS: The 33 of 480 individuals (7%) who developed ESRD had prior albuminuria. 71 of 480 (15%) individuals developed low eGFR. 66 of 71 (93%) had prior/concurrent albuminuria, and 5 of 71 (7%) did not. Incident low eGFR values in the 5 patients were: (1) 54, (2) 58, (3) 59, (4) 59.7, and (5) 59.8 mL/min/1.73 m(2). 3 of 5 (60%; patients 1, 4, and 5) subsequently developed albuminuria. Final eGFRs in the 5 patients were: (1) 94, (2) 86, (3) 60, (4) 65, and (5) 54 mL/min/1.73 m(2), respectively. LIMITATIONS: GFR and insulin sensitivity were not measured, but estimated. Incident decreased eGFR in patients without preceding/concurrent albuminuria may be caused by misclassification or a temporary eGFR decrease. CONCLUSIONS: Moderately decreased eGFR may occur rarely in patients with type 1 diabetes without preceding albuminuria.
Authors: P Bjornstad; T Costacou; R G Miller; D M Maahs; M J Rewers; T J Orchard; J K Snell-Bergeon Journal: Diabet Med Date: 2017-08-14 Impact factor: 4.359
Authors: Maryam Afkarian; Sarit Polsky; Afshin Parsa; Ronnie Aronson; Maria Luiza Caramori; David Z Cherney; Jill P Crandall; Ian H de Boer; Thomas G Elliott; Andrzej T Galecki; Allison B Goldfine; J Sonya Haw; Irl B Hirsch; Amy B Karger; Ildiko Lingvay; David M Maahs; Janet B McGill; Mark E Molitch; Bruce A Perkins; Rodica Pop-Busui; Marlon Pragnell; Sylvia E Rosas; Peter Rossing; Peter Senior; Ronald J Sigal; Catherine Spino; Katherine R Tuttle; Guillermo E Umpierrez; Amisha Wallia; Ruth S Weinstock; Chunyi Wu; Michael Mauer; Alessandro Doria Journal: Diabetes Care Date: 2019-06-11 Impact factor: 19.112
Authors: Scott G Frodsham; Zhe Yu; Ann M Lyons; Adhish Agarwal; Melissa H Pezzolesi; Li Dong; Titte R Srinivas; Jian Ying; Tom Greene; Kalani L Raphael; Ken R Smith; Marcus G Pezzolesi Journal: Diabetes Date: 2018-11-13 Impact factor: 9.461
Authors: Ian H de Boer; Maryam Afkarian; Tessa C Rue; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Wanjie Sun; Bernard Zinman Journal: J Am Soc Nephrol Date: 2014-06-12 Impact factor: 10.121
Authors: Maryam Afkarian; Leila R Zelnick; Yoshio N Hall; Patrick J Heagerty; Katherine Tuttle; Noel S Weiss; Ian H de Boer Journal: JAMA Date: 2016-08-09 Impact factor: 56.272
Authors: Mark E Molitch; Michael Steffes; Wanjie Sun; Brandy Rutledge; Patricia Cleary; Ian H de Boer; Bernard Zinman; John Lachin Journal: Diabetes Care Date: 2010-04-22 Impact factor: 19.112
Authors: Bruce A Perkins; Linda H Ficociello; Bijan Roshan; James H Warram; Andrzej S Krolewski Journal: Kidney Int Date: 2010-01 Impact factor: 10.612